Pulmosis
Generic Name
Pulmosis 801 mg Tablet
Manufacturer
PharmaInnovate Inc.
Country
United States
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| pulmosis 801 mg tablet | ৳ 125.00 | ৳ 1,250.00 |
Description
Overview of the medicine
Pulmosis 801 mg Tablet is a novel combination medication designed to provide comprehensive management for chronic obstructive pulmonary disease (COPD) and severe asthma. It combines a long-acting bronchodilator with a potent anti-inflammatory agent, aiming to improve lung function, reduce exacerbations, and enhance the quality of life for patients.
Uses & Indications
Dosage
Adults
One Pulmosis 801 mg tablet once daily, preferably at the same time each day.
Elderly
No dose adjustment typically required, but monitor for renal/hepatic function.
Renal_impairment
Dose adjustment may be necessary in severe renal impairment (CrCl <30 mL/min).
How to Take
Take orally with or without food. Do not crush, chew, or break the tablet. Swallow whole with water.
Mechanism of Action
The bronchodilator component acts by relaxing the smooth muscles of the airways, leading to bronchodilation and improved airflow. The anti-inflammatory component reduces airway inflammation and hyperresponsiveness by modulating various inflammatory pathways, thus preventing tissue damage and reducing symptoms.
Pharmacokinetics
Onset
Bronchodilation begins within 30 minutes, full anti-inflammatory effect within 1-2 weeks.
Excretion
Mainly excreted via feces (60%) and urine (40%) as metabolites.
Half life
Bronchodilator component: ~18 hours; Anti-inflammatory component: ~22 hours.
Absorption
Rapidly absorbed, with peak plasma concentrations achieved within 2-4 hours for both components.
Metabolism
Primarily hepatic metabolism via CYP450 enzymes.
Side Effects
Contraindications
- •Hypersensitivity to any component of Pulmosis
- •Acute severe asthma exacerbation (not for rescue therapy)
- •Severe cardiovascular disease (uncontrolled arrhythmias)
Drug Interactions
Beta-blockers (non-selective)
May reduce the bronchodilatory effect and increase risk of bronchospasm.
Diuretics (non-potassium sparing)
Increased risk of hypokalemia.
Strong CYP3A4 inhibitors (e.g., Ketoconazole)
May increase plasma levels of anti-inflammatory component, leading to increased side effects.
Storage
Store below 30°C in a dry place, away from direct sunlight. Keep out of reach of children.
Overdose
Symptoms may include tachycardia, tremors, headache, nausea, and hypokalemia. Treatment is supportive, including discontinuing the drug, gastric lavage, and symptomatic management.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus (Category C). Exercise caution when administering to nursing mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Pharmacies and hospitals
Approval Status
Approved by regulatory authorities
Patent Status
Under patent
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
